Johns Hopkins HIV Guide
Pyrazinamide
INDICATIONS
FDA
FDA
- TB (active treatment in combination with other antituberculous drugs)
- Treatment of active tuberculosis (in combination with other antituberculous drugs); no longer recommended for treatment of latent tuberculosis infection because of hepatotoxicity.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 7, 2026
Citation
Soto, Caitlin, and Edina Avdic. "Pyrazinamide." Johns Hopkins HIV Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545174/all/Pyrazinamide.
Soto C, Avdic E. Pyrazinamide. Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545174/all/Pyrazinamide. Accessed August 20, 2026.
Soto, C., & Avdic, E. (2026). Pyrazinamide. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545174/all/Pyrazinamide
Soto C, Avdic E. Pyrazinamide [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. [cited 2026 August 20]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545174/all/Pyrazinamide.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Pyrazinamide
ID - 545174
A1 - Soto,Caitlin,PharmD, BCIDP
AU - Avdic,Edina,Pharm.D.
Y1 - 2026/08/07/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545174/all/Pyrazinamide
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
